BMY
Bristol-Myers Squibb Company
62.50$
+1.8%
vs. previous close
Closing price · As of: Oct 30, 2026
Statements
Income Statement
Bristol-Myers Squibb Company (BMY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Revenue" came in at 48,195 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15,879 | 16,560 | 19,427 | 20,776 | 22,561 | 26,145 | 42,518 | 46,385 | 46,159 | 45,006 | 48,300 | 48,195 | |
| 3,932 | 3,909 | 4,969 | 6,014 | 6,467 | 8,078 | 11,773 | 9,940 | 10,137 | 10,693 | 13,968 | 13,936 | |
| 11,947 | 12,651 | 14,458 | 14,762 | 16,094 | 18,067 | 30,745 | 36,445 | 36,022 | 34,313 | 34,332 | 34,259 | |
| 4,534 | 5,920 | 5,012 | 6,468 | 6,332 | 6,148 | 11,143 | 10,195 | 9,509 | 9,299 | 11,159 | 9,951 | |
| 877 | 160 | 91 | 162 | 4,551 | 4,871 | 7,661 | 7,688 | 7,814 | 6,278 | 6,365 | 5,660 | |
| 10,233 | 10,921 | 9,991 | 11,316 | 10,980 | 12,154 | 28,568 | 27,908 | 26,918 | 26,118 | 28,445 | 20,535 | |
| 1,714 | 1,730 | 4,467 | 3,446 | 5,114 | 5,913 | 2,177 | 8,537 | 9,104 | 8,195 | 5,887 | 13,724 | |
| 203 | 184 | 167 | 196 | 183 | 656 | 1,420 | 1,334 | 1,232 | 1,166 | 1,947 | 1,891 | |
| 2,381 | 2,077 | 5,915 | 5,131 | 5,968 | 4,975 | -6,871 | 8,098 | 7,713 | 8,440 | -8,379 | 9,328 | |
| 352 | 446 | 1,408 | 4,156 | 1,021 | 1,515 | 2,124 | 1,084 | 1,368 | 400 | 554 | 2,272 | |
| 2,004 | 1,565 | 4,457 | 1,007 | 4,920 | 3,439 | -9,015 | 6,994 | 6,327 | 8,025 | -8,948 | 7,054 | |
| 3,051 | 2,637 | 6,464 | 6,116 | 6,788 | 7,377 | 4,929 | 20,118 | 19,221 | 19,366 | 3,168 | 15,230 |
Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.